Total Funding
31
30
Total FundingSeries A raised
Growth Score
-2 pts
Heat Score
-30 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
218791
BliNK Biomedical is specializes in the discovery and development of first or best-in-class antibody-based therapeutics.
- Jack Elands: Chief Executive OfficerPast Role: Emergence Therapeutics, Co-founder and Chief Executive Officer
About the Company
BliNK Biomedical SAS specializes in the discovery and development of first or best-in-class antibody-based therapeutics for life threatening diseases such as cancer with a focus on immuno-oncology disease targets. Our lead program is a monoclonal antibody that targets an immune checkpoint to cause an immune switch that renders tumors susceptible to
the body's immune system. Our other programs address a number of attractive, novel immuno-oncology and immune-checkpoint targets, some of which are unique to our approach. The antibodies that we are developing have the potential to be the next generation of anti-tumor therapeutics.
